Ravindran Kanesvaran, Chairman and Senior Consultant of the Division of Medical Oncology at the National Cancer Centre Singapore, shared a post on LinkedIn:
“Excited to officially launch the Research Institute for Cancer Prevention, Screening and Early Detection (RISE), jointly led by the National Cancer Centre Singapore and LKCMedicine, together with my co-director, Prof Jon Emery.
RISE aims to advance research, policy and implementation in cancer prevention and early detection — not just for Singapore, but across the region. As cancer incidence continues to rise globally, the need to shift healthcare upstream towards prevention, risk stratification and earlier diagnosis has never been more important.
We are proud to announce two major studies that will begin in 2026, including a Singapore clinical trial evaluating multi-cancer early detection (MCED) tests in high-risk individuals, as well as targeted cancer screening approaches linked to metabolic risk factors such as obesity, diabetes and hypertension.
These efforts are aligned with Singapore’s broader preventive health strategy and will help generate much-needed Asian data to guide future screening policies and implementation.
Grateful to all our partners, collaborators and supporters who made this possible. The work starts now.”
Other articles featuring Ravindran Kanesvaran on OncoDaily.